News - Pfizer, Neurological


Current filters:


Popular Filters

1 to 25 of 58 results

FDA advisory panel ambivalent on NSAID cardiovascular risk

FDA advisory panel ambivalent on NSAID cardiovascular risk


The US Food and Drug Administration’s joint Arthritis Advisory Committee and Drug Safety and Risk Management…

Anti-Arthritics/RheumaticsBayerNaproxenNeurologicalNorth AmericaPfizerPharmaceuticalUSA

Pfizer’s ALO-02 meets efficacy endpoint in Ph III

Pfizer’s ALO-02 meets efficacy endpoint in Ph III


US pharma behemoth Pfizer has released top-line results from a Phase III study of ALO-02 (oxycodone HCl…


Nippon Shinyaku and Pfizer conclude exclusive sales promotion on Tramal


Nippon Shinyaku and Pfizer have concluded an exclusive sales promotion consignment contract in Japan…

Asia-PacificLicensingMarkets & MarketingNeurologicalNippon ShinyakuPfizerPharmaceuticalTramadol Hydrochloride

Karo Bio gets first milestone in Pfizer collaboration


Under its collaboration with US pharma behemoth Pfizer (NYSE: PFE), Sweden's Karo Bio (STO: KARO) says…

Anti-Arthritics/RheumaticsDermatologicalsFinancialKaro BioLicensingNeurologicalPfizerPharmaceuticalResearch

Abcam in deal with Pfizer to supply compounds to researchers


UK-based Abcam (AIM: ABC), a producer and distributor of protein research tools, has entered into a license…


Lilly drops enzastaurin development; Remoxy future viewed by Pfizer and partners


US drug major Eli Lilly (NYSE: LLY) revealed that Phase III clinical trial results from enzastaurin's…

DurectEli LillyenzastaurinNeurologicalOncologyPain TherapeuticsPfizerPharmaceuticalRegulationRemoxyResearch

New York parents charge Pfizer for concealing true risks of birth defects linked to Zoloft


A law suit against pharmaceutical giant Pfizer (NYSE: PFE), for the permanent and devastating injuries…

LegalMarkets & MarketingNeurologicalNorth AmericaPfizerPharmaceuticalZoloft

GSK returns IPX066 rights to Impax; Merck & Co and Pfizer link up on diabetes drug


US biotech firm Impax Laboratories (Nasdaq: IPXL) saw its shares fall 2% to $17.32 in premarket trading,…

BiotechnologyDiabetesertugliflozinGlaxoSmithKlineImpax LaboratoriesIPX066LicensingMerck & CoNeurologicalPfizerPharmaceuticalResearch

Appeals Court rules against EMD Serono over Rebif deal with Pfizer


Germany's Merck KGaA (MRK: DE) says that a Pennsylvania appeals court has ruled against Merck in deciding…

BiotechnologyEMD SeronoLegalMarkets & MarketingMerck KGaANeurologicalNorth AmericaPfizerPharmaceuticalRebif

Ranbaxy in deal with Alembic to market bioequivalent Pristiq in USA


The US subsidiary of India's largest drugmaker, Ranbaxy Laboratories (AB: BO), which is majority owned…

Alembic PharmaceuticalsDaiichi SankyoGenericsLicensingMarkets & MarketingNeurologicalNorth AmericaPatentsPfizerPristiqRanbaxy Laboratories

Pfizer's Lyrica equals levetiracetam in patients with partial onset seizures


Global pharma behemoth Pfizer (NYSE: PFE) has announced top-line results from a Phase III study showing…


Research results for Pfizer's Chantix, Pristiq and Toviaz


Global drugs behemoth Pfizer (NYSE: PFE) last week released a batch of new clinical trial data relating…


Pfizer's Quillivant XR oral suspension now available in USA; GlaxoSmithKline files BLA for albiglutide


Confirming expectations announced when Pfizer (NYSE: PFE) revealed its $680 million acquisition of NextWave…

albiglutideDiabetesGlaxoSmithKlineMarkets & MarketingNeurologicalNorth AmericaPfizerPharmaceuticalQuillivantRegulation

Repligen in $70 million deal with Pfizer for SMA program


USA-based Repligen (Nasdaq: RGEN) saw its share jump 5.6% to $6.63, after the company revealed it has…

BiotechnologyLicensingNeurologicalPfizerPharmaceuticalRare diseasesRepligenRG3039

US FDA approves Merck KGaA's Rebif Rebidose


German drug major Merck KGaA's (MRK: DE) US subsidiary EMD Serono and pharma behemoth Pfizer (NYSE: PFE)…

BiotechnologyEMD SeronoMerck KGaANeurologicalNorth AmericaPfizerPharmaceuticalRebifRegulation

Japanese approvals for Novo's Ryzodeg, UCB/Otsuka's Neupro and B-MS/Pfizer's Eliquis


Danish insulin giant Novo Nordisk (NOVN: NV) revealed on December 15 that the Japanese Ministry of Health,…

Asia-PacificBristol-Myers SquibbCardio-vascularDiabetesEliquisNeuproNeurologicalNovo NordiskOtsukaPfizerPharmaceuticalRegulationRyzodegUCB

Insights on the US Alzheimer's disease market


The treatment of Alzheimer's disease (AD) offers a compelling commercial opportunity for the pharmaceutical…

AriceptEisaiExelonForest LaboratoriesGenericsMarkets & MarketingNamendaNeurologicalNorth AmericaNovartisPfizerPharmaceutical

Pfizer's Lyrica misses primary endpoint in seizure frequency trial; positive in fibromyalgia


US pharma behemoth Pfizer (NYSE: PFE) revealed disappointing top-line results of a double-blind, placebo-controlled,…


1 to 25 of 58 results

Back to top